Patients with certain KLK-6 mutations at risk for aggressive forms of prostate cancer

A newly published article in the Journal of the National Cancer Institute has suggested that men carrying a particular genetic mutation in the kallikrein 6 gene (KLK-6) have an increased risk for aggressive, clinically significant prostate cancer. … READ MORE …

“Why gene tests for cancer don’t offer more answers”

An article with the above title appears to be scheduled for upcoming publication in Scientific American but is already available on line on the Scientific American web site. It may be of interest to a number of our readers. … READ MORE …

Prevalence of DNA-repair germline mutations in men with metastatic prostate cancer

A new study in this week’s New England Journal of Medicine reports that DNA-repair germline mutations were found in nearly 12 percent of patients who had metastatic prostate cancer. … READ MORE …

A potential future for prostate cancer risk assessment

A recent article in the International Journal of Cancer lays out a possible future scenario for prostate cancer risk assessment that takes specific account of familial and hereditary risks for clinically significant prostate cancer. … READ MORE …

Poorer outcomes for BRCA1/2 carriers after standard treatment

It is not entirely surprising to come across a paper suggesting that male carriers of the BRCA1/2 genes are at risk for worse post-treatment outcomes than non-carriers of these genes after standard forms of first-line treatment for prostate cancer. … READ MORE …

Rare G84E mutation strongly associated with familial (inherited) prostate cancer

A new study has confirmed an initial finding that the rare G84E mutation (also known as rs138213197) in the HOXB13 gene is a significant driver of risk for prostate cancer among men with a family history of the disease. … READ MORE …

Do SPOP mutations define a new molecular subtype of prostate cancer?

A Letter to the Editor just published in the journal Nature Genetics has suggested that that so-called SPOP mutations may be responsible for between 6 and 15 percent of the prostate cancers diagnosed in the USA each year. … READ MORE …